New CDC surveillance data published in the Morbidity and Mortality Weekly Report (MMWR) reveals that half of all patients diagnosed with invasive mold diseases require mechanical ventilation. According to the U.S. Centers for Disease Control and Prevention, recent SARS-CoV-2 infection significantly worsens these outcomes, driving the 90-day all-cause mortality rate up to 66% among affected individuals.
Severe Respiratory Support and ICU Demands
Critical respiratory support remains a defining feature of invasive mold disease (IMD) management, according to the surveillance summary tracking cases across four Atlanta hospitals from 2020 to 2024. Researchers found that 50% of the 449 identified patients required invasive mechanical ventilation. Furthermore, 43% of these patients required intensive care unit admission in the two weeks leading up to their formal diagnosis. Pulmonary infections dominated the clinical picture, accounting for 68% of all recorded diagnoses, while the overall 90-day all-cause mortality rate for the entire cohort settled at 45%.
COVID-19 Complications Drive Up Mortality Rates
Recent coronavirus diagnoses correlate heavily with severe complications and starkly elevated death rates among IMD patients, according to the CDC report. Approximately 13% of patients tracked in the surveillance period carried a current or recent COVID-19 diagnosis. These individuals faced a 66% ICU admission rate during the two weeks prior to specimen collection, compared to 39% for patients without the virus. Consequently, the 90-day all-cause mortality rate for IMD patients with recent COVID-19 reached 66%, vastly exceeding the 41% mortality seen in patients who did not contract the virus.
Did you know?
Aspergillus species appeared in 71% of all reported invasive mold disease cases, with Aspergillus fumigatus alone accounting for 21% of the total pathogen identifications.
Shifting Patient Demographics and Risk Factors
Traditional immunocompromising conditions no longer capture every patient vulnerable to severe fungal infections, as the data shows over 35% of cases occurred in individuals lacking classic host risk factors. Established criteria from the National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group (MSG)—such as neutropenia, hematologic malignancy, or organ transplantation—failed to appear in more than a third of the diagnosed population. While solid organ transplants accounted for 27% of cases and hematologic malignancies accounted for 22%, the CDC notes that surveillance relying solely on traditional markers risks missing a substantial portion of patients suffering from conditions like cirrhosis, end-stage renal disease, and severe burns.
Treatment Trends and Healthcare Facility Incidence
Managing invasive mold diseases requires prolonged antifungal therapy, with 81% of patients receiving medications specifically effective against molds, according to the surveillance summary. Isavuconazole led treatment regimens at 40%, followed by voriconazole at 32% and amphotericin B at 21%. Meanwhile, incidence rates varied starkly between facility types. Academic hospitals reported a pooled average annual incidence of 4.8 inpatient cases per 100 inpatient beds and 14.0 ICU cases per 100 ICU beds. Community hospitals reported lower averages of 2.8 inpatient cases per 100 beds and 10.2 ICU cases per 100 beds, as logged through the National Healthcare Safety Network.
Frequently Asked Questions
What percentage of invasive mold disease patients require mechanical ventilation?
According to CDC surveillance data, 50% of patients diagnosed with invasive mold diseases require invasive mechanical ventilation.
How does a recent COVID-19 diagnosis affect invasive mold mortality?
Patients with invasive mold disease and a recent COVID-19 diagnosis experience a 90-day all-cause mortality rate of 66%, compared to 41% for patients without the virus.
Do all patients with invasive mold infections have traditional risk factors?
No, over 35% of cases occur in patients who do not possess classic host risk factors such as transplants, neutropenia, or hematologic malignancies.
Which fungal species is most commonly identified in these infections?
Aspergillus species are the most common, appearing in 71% of all invasive mold disease cases.
Join the Conversation: Share your thoughts on these findings or subscribe to our newsletter for the latest updates in public health surveillance and clinical research.
Related reading